Filing Details

Accession Number:
0001415889-25-002003
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-01-23 20:36:55
Reporting Period:
2025-01-23
Accepted Time:
2025-01-23 20:36:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1438533 Travere Therapeutics Inc. TVTX Pharmaceutical Preparations (2834) 262383102
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1680739 D. Roy Baynes C/O Travere Therapeutics, Inc.
3611 Valley Centre Dr., Suite 300
San Diego CA 92130
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2025-01-23 16,000 $17.50 47,000 No 4 M Direct
Common Stock Disposition 2025-01-23 16,000 $20.00 31,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2025-01-23 16,000 $0.00 16,000 $17.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2026-07-19 No 4 M Direct
Footnotes
  1. This sale was made pursuant to a written plan adopted on August 16, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on July 19, 2016, with an expiration date of July 19, 2026.
  2. The stock option is fully vested and exercisable.